Tiger Global Management Co-Invests $133M In China’s B2B Pharma Trading Firm Yaoshibang

Eudora Wang
December 17, 2018 — 12:22 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: B2B China chinese DCM Green Pine Capital guangdong Guangzhou healthcare medicine pharmaceutical real estate shenzhen Tiger global management venture capital Website Yaoshibang Zhang Buzhen

Related News:

China Accelerates Artificial Sun Efforts With State and Private Firms Pursue Breakthroughs in Controlled Nuclear Fusion

January 12, 2024 — 01:11

Investors Flock to New Materials, Boosting Domestic Replacement Tech and Low Carbon Economy

December 29, 2023 — 02:31

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

China Establishes Nationwide Regulations for Commercial Use of Autonomous Vehicles

December 6, 2023 — 01:50

China’s Energy Sector Invests in Hydrogen Projects to Achieve National Dual Carbon Goals

December 4, 2023 — 23:32

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

ByteDance’s ChatGPT-Powered AI Chatbot Cici Tops Charts in Emerging Markets

November 29, 2023 — 23:23

Huawei Spins Off Intelligent Automotive Solutions Unit To Secure Fresh Funding

November 27, 2023 — 23:45

ByteDance Establishes New AI Division To Accelerate Consumer Product Deployment

November 27, 2023 — 23:10